Key result
NAVI-HF-detected congestion at discharge increased the risk of 6-month all-cause mortality or HF hospitalization (HR 1.59, p=0.03) in acute HFrEF patients, though attenuated after full adjustment.
Why the study?
The prognostic significance of a novel artificial intelligence auscultation device (NAVI-HF) for predicting clinical outcomes in predischarge acute HF patients required evaluation.
Does pulmonary congestion detected by the novel artificial intelligence auscultation device (NAVI-HF) predict composite all-cause mortality and heart failure hospitalization at 6 months in predischarge acute heart failure with reduced ejection fraction patients?
Cohort (n=239)
Yes
Does pulmonary congestion detected by the novel artificial intelligence auscultation device (NAVI-HF) predict composite all-cause mortality and heart failure hospitalization at 6 months in predischarge acute heart failure with reduced ejection fraction patients?
Predischarge pulmonary congestion detected by the AI-assisted auscultation device NAVI-HF identifies acute HFrEF patients with a higher-risk clinical profile and increased 6-month risk of heart failure rehospitalization and composite events, though its prognostic value is not independent of established risk markers like NT-proBNP and LVEF.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Its primary purpose is to help physicians identify high-risk patients at an earlier stage. With this simple and portable device, doctors can better assess whether a patient's condition is truly stable before discharge.”
NAVI-HF positivity may flag higher-risk acute HFrEF patients at discharge; hypothesis-generating and requires confirmation of independent value.
Aim This study evaluated the prognostic significance of a novel auscultation device of artificial intelligence (NAVI-HF) in predicting clinical outcomes in predischarge acute heart failure (HF) patients. Methods This second, prognostic phase of a prospective observational cohort study extends our prior diagnostics phase, in which NAVI-HF demonstrated good performance compared with lung ultrasound (LUS) B-lines as the reference standard. Patients were classified as NAVI-HF positive or negative prior to discharge and followed for 6 months for evaluation. Results A total of 239 patients were included of whom 111 (45.1%) were NAVI-HF positive. NAVI-HF positive patients had a worse clinical profile and higher NT-proBNP ( p < 0.05). During a median follow-up of 6 months, 82 composite events (34.3%) occurred. In univariate Cox analysis, NAVI-HF positive was associated with significant increased risk of composite outcome (HR 1.59, CI 1.03–2.47; p 0.03) and HF hospitalization (HR 1.64, CI 1.05–2.46; p 0.02), but not all-cause mortality (p 0.24). The association in composite and HF hospitalization outcomes remained significant after adjustment for age and sex but was attenuated after adjustment for other prognostic variables. Conclusion NAVI-HF–detected congestion was associated with increased adverse clinical outcomes in predischarge acute HF patients.
No takes yet. Share an insight, caveat, or question.
Santoso et al. (2026) conducted a cohort in Acute heart failure with reduced ejection fraction (HFrEF) (n=239). NAVI-HF positive (pulmonary congestion detected by AI auscultation device) vs. NAVI-HF negative (no pulmonary congestion detected) was evaluated on Composite of all-cause mortality and heart failure hospitalization at 6 months (HR 1.59, 95% CI 1.03-2.47, p=0.03). NAVI-HF-detected congestion at discharge increased the risk of 6-month all-cause mortality or HF hospitalization (HR 1.59, p=0.03) in acute HFrEF patients, though attenuated after full adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: